Dosing is complete in the Phase 3 REBUILD clinical trial testing INOpulse (inhaled nitric oxide) in people with pulmonary…
Articles by Patricia Inácio, PhD
One-year of high-dose AP01, Avalyn Pharma’s inhaled pirfenidone solution, slowed lung function decline in people with idiopathic pulmonary…
Individuals with idiopathic pulmonary fibrosis (IPF) who experience unintended weight loss are at significantly higher risks of being admitted…
CS Pharmaceuticals (CSP) has entered into an exclusive in-licensing agreement with Daewoong Pharmaceutical to develop and commercialize bersiporocin,…
Strados Labs is teaming up with Boehringer Ingelheim to conduct a pilot study leveraging its RESP Biosensor, a…
Changes in blood levels of Krebs von den Lungen-6 — a protein produced by certain lung cells and known as…
PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in…
Bridge Biotherapeutics has launched a Phase 2a clinical trial to assess the safety, tolerability, and effectiveness of BBT-877 in…
The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing…
Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with…